Arca
Skip to content
Tools
Tools

Label Changes: Monoferric (ferric derisomaltose)

A drug's label (its prescribing information) is revised many times after approval: new warnings, new uses, new doses. DailyMed keeps every version. Pick a drug to see them all and what changed between any two.

Every version of the Monoferric label DailyMed has published, from Pharmacosmos Therapeutics Inc., and what changed between any two of them, section by section. Current label on DailyMed.

  • Versions on DailyMed: 10
  • Sections changed, version 13 to 15: 14

What changed from version 13 to version 15

Dec 10, 2025 to Nov 4, 2026, as published on DailyMed. Added text is underlined in green, removed text struck through in red.
  1. Indications and usageChanged ยท 1 word added
  2. Dosage and administrationChanged ยท 101 words added, 1 removed
  3. ContraindicationsChanged ยท punctuation or symbols only
  4. Warnings and precautionsChanged ยท punctuation or symbols only
  5. Adverse reactionsChanged ยท 2 words added
  6. Use in specific populationsChanged ยท 299 words added, 238 removed
  7. OverdosageChanged ยท 18 words added
  8. DescriptionChanged ยท 10 words added, 23 removed
  9. Clinical pharmacologyChanged ยท 3 words added, 6 removed
  10. Clinical studiesChanged ยท 71 words added, 4 removed
  11. How suppliedChanged ยท 4 words added, 26 removed
  12. Patient counseling informationChanged ยท 18 words added
  13. Patient informationChanged ยท 444 words added, 386 removed
  14. Untitled sectionRemoved ยท 18 removed

Indications and usage

Changed1 word added
1 unchanged line
Monoferric is indicated for the treatment of iron deficiency anemia (IDA) in adult patients:
who have intolerance to oral iron or have had unsatisfactory response to oral iron, or
who have non-hemodialysis -dependent chronic kidney disease (NDD-CKD)

Dosage and administration

Changed101 words added, 1 removed
4 unchanged lines
The dosage of Monoferric is expressed in mg of elemental iron. Each mL of Monoferric contains 100 mg of elemental iron.
Only administer Monoferric when personnel and therapies are immediately available for the treatment of serious hypersensitivity reactions ([see Warnings and Precautions (5.1)) ].
2.2 Preparation and Administration
5 unchanged lines
Administer the prepared solution via intravenous infusion over at least 20 minutes.
Following dilution with 0.9% Sodium Chloride Injection, USP, Monoferric solution may be stored at room temperature [20ยฐ C to 25ยฐC (68ยฐF to 77ยฐF)] for up to 812 hours.
Extravasation of Monoferric may cause brown discoloration at the extravasation site which may be long lasting. Monitor for extravasation. If extravasation occurs, discontinue the Monoferric administration at that site.
Monitor patients for hypersensitivity reactions for 30 minutes after infusion completes.
2.3 Drug Compatibility
The Monoferric solution for administration at the final diluted concentration of > 1 mg iron/mL is compatible with:
Infusion bags of various volumes up to 500 mL of 0.9% sodium chloride injection, USP
100 mL of Baxterยฎ Mini-Bag PlusTM (and equivalent formats) containing 0.9% sodium chloride injection, USP
Transfer with Vial2Bag Advanced Admixture Devices to infusion bags of various volumes up to 500 mL of 0.9% sodium chloride injection, USP

Contraindications

Changedpunctuation or symbols only
4 CONTRAINDICATIONS
Monoferric is contraindicated in patients with a history of serious hypersensitivity to Monoferric or any of its components ([see Warnings and Precautions (5.1), Description (11)) ]. Reactions have included shock, clinically significant hypotension, loss of consciousness, and/or collapse.

Warnings and precautions

Changedpunctuation or symbols only
1 unchanged line
5.1 Hypersensitivity Reactions
Serious hypersensitivity reactions, including anaphylactic-type reactions, some of which have been life-threatening and fatal, have been reported in patients receiving Monoferric. Patients may present with shock, clinically significant hypotension, loss of consciousness, and/or collapse. Monitor patients for signs and symptoms of hypersensitivity during and after Monoferric administration for at least 30 minutes and until clinically stable following completion of the infusion. Only administer Monoferric when personnel and therapies are immediately available for the treatment of serious hypersensitivity reactions. Monoferric is contraindicated in patients with prior serious hypersensitivity reactions to Monoferric or any of its components ( [see Contraindications (4) )]. In clinical trials in patients with IDA and CKD, serious or severe hypersensitivity were reported in 0.3% (6/2008) of the Monoferric treated subjects. These included 3 events of hypersensitivity in 3 patients; 2 events of infusion-related reactions in 2 patients and 1 event of asthma in one patient.
5.2 Iron Overload
Excessive therapy with parenteral iron can lead to excess iron storage and possibly iatrogenic hemosiderosis or hemochromatosis. Monitor the hematologic response (hemoglobin and hematocrit) and iron parameters (serum ferritin and transferrin saturation) during parenteral iron therapy. Do not administer Monoferric to patients with iron overload ([see Overdosage (10)) ].

Adverse reactions

Changed2 words added
1 unchanged line
The following clinically significant adverse reactions are discussed in greater detail in other sections of the labeling:
Hypersensitivity Reactions ([see Warnings and Precautions (5.1)) ].
Iron Overload ([see Warnings and Precautions (5.2)) ].
6.1 Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed cannot be directly compared to rates in other clinical trials and may not reflect the rates observed in clinical practice.
The safety of Monoferric was evaluated in 3008 patients with iron deficiency anemia enrolled in two randomized, actively-controlled trials. Trial 1 enrolled adult patients with iron deficiency anemia with intolerance to oral iron or had an unsatisfactory response to oral iron with a clinical need for repletion of iron stores. Eligible subjects were required to have a baseline hemoglobin of โ‰ค11g/dl, transferrin saturation (TSAT) of less than 20% and serum ferritin level of <100 ng/mL. Trial 2 enrolled adult patients with non-dialysis dependent chronic kidney disease (CKD) with iron deficiency anemia ( [see Clinical Studies (14) )]. Eligible subjects also had to have serum ferritin โ‰ค100 ng/mL or โ‰ค300 ng/mL if TSAT โ‰ค30%.
Trial 1 and Trial 2
In the two randomized, actively-controlled clinical trials, Trial 1 and Trial 2 ([see Clinical Studies (14)) ], patients were randomized in a 2:1 ratio to intravenous Monoferric (n = 2008) or intravenous iron sucrose (n = 1000) respectively. Monoferric was administered as a single intravenous infusion of 1000 mg diluted in 100 mL 0.9 % sodium chloride and given over approximately 20 minutes (approximately 50 mg iron/min). Iron sucrose was administered as 200 mg undiluted intravenous injections over approximately 2-5 minutes and repeated according to standard practice or physician choice up to a maximum of five times (1000 mg) within the first two weeks starting at baseline.
The data described below reflect exposure to Monoferric in 2008 patients exposed to a 1000 mg single intravenous dose of Monoferric. The mean cumulative intravenous Iron exposure was 984 mg.
11 unchanged lines
Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The following adverse reactions have been most commonly reported from the post-marketing spontaneous reports with Monoferric:
Cardiac disorders: Tachycardia, arrhythmia
Gastrointestinal disorders: Abdominal pain, nausea and vomiting, constipation, diarrhea, dyspepsia
General disorders and administration site conditions: Fatigue, pyrexia, chest pain, chills, Fishbane reaction, extravasation, influenza like symptoms, injection site reactions, malaise, pain
9 unchanged lines

Use in specific populations

Changed299 words added, 238 removed
2 unchanged lines
Risk Summary
There are no available data on Monoferric use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Published studies on the use of intravenous iron products in pregnant women have not reported an association with adverse developmental outcomes. However, these studies cannot establish or exclude the absence of any drug-related risk during pregnancy because the studies were not designed to assess for the risk of major birth defects ( see Data) . There are risks to the mother and fetus associated with untreated iron deficiency anemia (IDA) in pregnancy as well as risks to the fetus associated with maternal severe hypersensitivity reactions ( see Clinical Considerations) . Iron complexes have been reported to be teratogenic and embryocidal in non-iron depleted pregnant animals. The findings in animals may be due to iron overload and may not be applicable to patients with iron deficiency. Animal reproduction studies of ferric derisomaltose administered to rats and rabbits during the period of organogenesis caused adverse developmental outcomes including structural abnormalities and embryo-fetal mortality at doses approximately 0.09 and 0.4 times the maximum recommended human dose (MRHD) of 1000 mg, respectively, based on body surface area ( see Data) .
Available data from published studies and postmarketing reports with Monoferric have not identified a risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes (see Data). There are risks to the mother and fetus associated with untreated iron deficiency anemia in pregnancy as well as risks to the fetus associated with maternal severe hypersensitivity reactions (see Clinical Considerations).
In animal studies, administration of Monoferric to pregnant rabbits during organogenesis caused adverse developmental outcomes including fetal malformations and decreased fetal weights at 0.5 times the maximum recommended human dose of 1000 mg based on body surface area (see Data ).
The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. AdverseAll outcomespregnancies inhave pregnancya occurbackground regardlessrisk of the health ofbirth thedefect, motherloss, or the useother ofadverse medicationsoutcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2- to 4% and 15- to 20%, respectively.
Clinical Considerations
Disease-associated maternal and/or embryo/fetal risk
Untreated iron deficiency anemia (IDA) in pregnancy is associated with adverse maternal outcomes such as post-partum anemia. Adverse pregnancy outcomes associated with IDA, in the mother and/or fetus, includes increased risk for preterm delivery and low birth weight.
Fetal/Neonatal adverse reactions
1 unchanged line
Data
Human Data
In a randomized study, 201 pregnant women in the second trimester of pregnancy (gestational weeks 14 to 21) were randomized to receive either ferric derisomaltose as a single intravenous infusion of 1000 mg (n=100) or oral ferrous fumarate with ascorbic acid administered once daily for 18 weeks as a tablet of 330mg ferrous fumarate (equivalent to 100mg elemental iron) (n=101). The safety profile was comparable between ferric derisomaltose and oral iron based on adverse events and laboratory safety parameters.
Animal Data
Iron complexes have been reported to be teratogenic and embryocidal in non-anemic pregnant animals at single doses above 125 mg iron/kg body weight. The highest recommended dose in human clinical use is 20 mg iron/kg body weight.
Animal reproduction studies of ferric derisomaltose administered to rats and rabbits during the period of organogenesis caused adverse developmental outcomes including structural abnormalities and embryo-fetal mortality at doses approximately 0.09 and 0.4 times the maximum recommended human dose (MRHD) of 1000 mg, respectively, based on body surface area (BSA). The findings in animals may be due to iron overload and may not be applicable to patients with iron deficiency.
In a combined fertility and embryo-fetal development study in rats, ferric derisomaltose was administered intravenously to female rats 14 days prior to cohabitation and through gestation day (GD) 17 at doses of 3, 11, and 32 mg Fe/kg/day. The doses of 11 and 32 mg Fe/kg/day (approximately 0.1 and 0.3 times the MRHD of 1000 mg, based on body surface area (BSA)) resulted in an increase in the incidence of skeletal developmental delays.
Ferric derisomaltose was administered intravenously to pregnant rabbits during organogenesis, from GD7 to GD20, at doses of 11, 25 and 43 mg Fe/kg/day. The dose of 43 mg Fe/kg/day (approximately 0.8 times the MRHD of 1000 mg, based on BSA) resulted in increased maternal mortality, abortion, and premature delivery, and increased postimplantation loss. Adverse developmental findings at this dose included fetal mortality, reduced fetal weights, and fetal developmental variations and malformations (including domed head, cleft palate, microglossia, hydrocephaly, small brain). Fetal malformations and reduced fetal weights were also noted in the 25 mg Fe/kg/day group (approximately 0.5 times the MRHD based on BSA).
1 unchanged line
Risk Summary
The available data onA theclinical usestudy ofwith Monoferric inadministered to lactating women demonstrateshowed thattransfer ironof isiron presentto inthe breast milk with mean iron concentrations within normal range at all samples times. However, the data do not inform the potential exposure of iron for the breastfed child or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Monoferric in addition to any potential adverse effects on the breastfed child from the drug or from the underlying maternal condition.
Clinical Considerations
5 unchanged lines

Overdosage

Changed18 words added
10 OVERDOSAGE
Excessive dosages of Monoferric may lead to accumulation of iron in storage sites potentially leading to hemosiderosis and hemochromatosis. Avoid use of Monoferric in patients with iron overload ([see Warnings and Precautions (5.2)]. Consider contacting the Poison Help line (1-800-222-1222) or a medical toxicologist for overdose management recommendations.

Description

Changed10 words added, 23 removed
2 unchanged lines
Ferric derisomaltose has an average molecular weight of 155,000 Da and has the following empirical formula:
| {FeO (1-3X) (OH) (1+3X) (C 6H 5O 7C6H5O7 3-) X}, (H 20H20) T, -
(C 6H 10O 6) R(-C 6H 10O 5-) Z(C 6H 13O 5) R, (NaCl) Y
| (C6H10O6)R(-C6H10O5-)Z(C6H13O5)R, (NaCl)Y
| X = 0.0311; T = 0.25; R = 0.14; Z = 0.49; Y = 0.14
Iron atoms placed in the electronegative cavities of the 3-D structure between and within the derisomaltose molecules. A schematic representation is presented below
Monoferric is a sterile, dark brown, non-transparent aqueous solution with pH 5.0-7.0, containing ferric derisomaltose dissolved in water for injections and filled into Type I glass vials.
Each 1 mL of solution contains 100 mg of elemental iron as ferric derisomaltose in water for injection,; hydrochloric acid and sodium hydroxide may be used to adjust pH.

Clinical pharmacology

Changed3 words added, 6 removed
8 unchanged lines
The pharmacokinetics of total iron (derisomaltose-bound plus transferrin-bound iron) were evaluated in adult patients with IDA.
After a single dose of Monoferric, maximum concentration (C maxCmax) and area under the concentration time curve (AUC) of serum total iron increased approximately proportionally over the 100 to 1000 mg dose range. After a 1000 mg single dose, the C maxCmax and AUC infAUCinf of total iron (geometric mean and CV%) of serum total iron were 408 (10.5) ฮผg/mL and 17730 (22.1) ฮผg.h /mL.
Distribution
5 unchanged lines

Clinical studies

Changed71 words added, 4 removed
5 unchanged lines
Table 2. Change in Hemoglobin Endpoints in Trial 1
1Least square mean
2The estimate is from a mixed model for repeated measures with treatment, week, treatment-by-week and stratum as fixed effects and baseline Hb and baseline-by-week as covariates.
Trial 1 | Monoferric N = 1009 | Iron sucrose N = 503 | Difference
Mean change in Hb from Baseline to Week 8 MeanMean1 (95% CI), g/dL (Primary endpoint) | 2.49 (2.41;2.56) | 2.49 (2.38;2.59) | Estimate Estimate2: 0.00 (95% CI -0.13;0.13) Non-inferiority confirmed
Iron Deficiency Anemia in Patients with Non-Hemodialysis Dependent Chronic Kidney Disease (NDD-CKD)
2 unchanged lines
Table 3. Change in Hemoglobin Endpoints in Trial 2
1Least square mean
2 The estimate is from a mixed model for repeated measures with treatment, week, treatment-by-week and stratum as fixed effects and baseline Hb and baseline-by-week as covariates.
Trial 2 | Monoferric N = 1027 | Iron sucrose N = 511 | Difference
Mean change in Hb from Baseline to Week 8 MeanMean1 (95% CI), g/dL (Primary endpoint) | 1.22 (1.14;1.31) | 1.14 (1.03;1.26) | Estimate Estimate2: 0.08 (95% CI -0.06;0.23) Non-inferiority confirmed

How supplied

Changed4 words added, 26 removed
7 unchanged lines
16.2 Storage and Handling
Store at 20ยฐ C to 25ยฐC (68ยฐF to 77ยฐF); excursions permitted to 15ยฐ C to 30ยฐC (59ยฐF to 86ยฐF). See the USP controlled room temperature.
Do not freeze.
When added to an infusion bag containing 0.9% Sodium Chloride Injection, USP, Monoferric solution may be stored for up to 8 hours at room temperature.

Patient counseling information

Changed18 words added
2 unchanged lines
Prior History of Allergies to Parenteral Iron Products
Question patients regarding any prior history of reactions to parenteral iron products ([see Warnings and Precautions (5.1)) ].
Hypersensitivity Reactions
Advise patients to report any signs and symptoms of hypersensitivity that may develop during and following Monoferric administration, such as rash, itching, dizziness, lightheadedness, swelling and breathing problems ([see Warnings and Precautions (5.1)) ].
Distributed by: Pharmacosmos Therapeutics Inc., Morristown, NJ 07960
Monoferric is manufactured under license from Pharmacosmos A/S, Denmark

Patient information

Changed444 words added, 386 removed
8ThisThis Patient Information has been approved by the U.S. Food and Drug Administration. | Issued:Revised 0210/20202026
Patient Information MONOFERRIC (mon-oh-fer-ik) (ferric derisomaltose) Injection
PATIENT INFORMATION MONOFERRIC (mon-oh-fer-ik) (ferric derisomaltose) injection, for intravenous use
What is MONOFERRIC? MONOFERRIC is a prescription iron replacement medicine used to treat iron deficiency anemia in adults who have: intolerance to oral iron or who have not responded well to treatment with oral iron non-dialysis dependent chronic kidney disease It is not known if MONOFERRIC is safe and effective for use in children less than 18 years old.
What is Monoferric? Monoferric is a prescription iron replacement medicine used to treat iron deficiency anemia in adults who: cannot tolerate oral iron (taken by mouth) or have not responded well to treatment with oral iron, or have chronic kidney disease that does not require dialysis.
It is not known if MONOFERRIC is safe and effective for use in children.
Who should not receive MONOFERRICMonoferric? Do not receive MONOFERRICMonoferric if you are allergic to ferric derisomaltoseMonoferric or any of the ingredients in MONOFERRICMonoferric. See the end of this leaflet for a complete list of ingredients in MONOFERRICMonoferric.
Before receiving MONOFERRIC, tell your healthcare provider about all of your medical conditions, including if you: have had an allergic reaction to IV iron are pregnant or plan to become pregnant. It is not known if MONOFERRIC will harm your unborn baby. are breastfeeding or plan to breastfeed. MONOFERRIC passes into your breast milk and may harm your baby. Talk to your healthcare provider about the best way to feed your baby during treatment with MONOFERRIC. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Know the medicines you take. Keep a list of them to show to your healthcare provider and pharmacist when you get a new medicine.
Before receiving Monoferric, tell your healthcare provider about all of your medical conditions, including if you: have had an allergic reaction to iron given by intravenous (IV) infusion. are pregnant or plan to become pregnant. It is not known if Monoferric will harm your unborn baby. are breastfeeding or plan to breastfeed. Monoferric passes into your breast milk . Talk to your healthcare provider about the best way to feed your baby during treatment with Monoferric.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Know the medicines you take. Keep a list of them to show to your healthcare provider and pharmacist when you get a new medicine.
How will I receive MONOFERRIC? MONOFERRIC is given into your vein (intravenously) by your healthcare provider over at least 20 minutes.
How will I receive Monoferric? Monoferric is given into your vein (intravenously) by your healthcare provider over at least 20 minutes. Your healthcare provider will monitor you for allergic reactions for at least 30 minutes after you receive Monoferric. Monoferric may cause a brown stain or discoloration of your skin at the infusion site if the IV fluid leaks under your skin (extravasation). The brown stain or discoloration can last a long time. Tell your healthcare provider right away if you see any leaking or swelling at the infusion site.
What are the possible side effects of MONOFERRIC? MONOFERRIC may cause serious side effects, including: Allergic (hypersensitivity) reactions. Serious life-threatening allergic reactions have happened in people who receive MONOFERRIC. Symptoms of an allergic reaction including rash, itching, hives, dizziness, lightheadedness, breathing problems and low blood pressure have also happened during treatment with MONOFERRIC. Tell your healthcare provider right away if you develop any of the above symptoms of a serious allergic reaction or if you have ever had any unusual or allergic reaction to any IV iron in the past. Too much iron stored in your body (iron overload). Your healthcare provider should check the iron level in your blood before you start and during treatment with MONOFERRIC. The most common side effects of MONOFERRIC include rash and nausea. These are not all the possible side effects of MONOFERRIC. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What are the possible side effects of Monoferric? Monoferric may cause serious side effects, including: Allergic (hypersensitivity) reactions. Serious life-threatening allergic reactions have happened in people who receive Monoferric. Tell your healthcare provider right away if you develop any symptoms of a serious allergic reaction, including: rash itching hives swelling of your face, lips, mouth, or tongue trouble breathing wheezing chest discomfort feeling faint, dizzy, or lightheaded Too much iron stored in your body (iron overload). Your healthcare provider should check the iron level in your blood before you start and during treatment with Monoferric.
The most common side effects of Monoferric include rash and nausea. These are not all the possible side effects of Monoferric. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
General information about MONOFERRICMonoferric Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. You can ask your pharmacist or healthcare provider for information about MONOFERRICMonoferric that is written for health professionals.
What are the ingredients in MONOFERRICMonoferric? Active ingredient: ferric derisomaltose Inactive ingredients: water for injection. Hydrochloric acid and sodium hydroxide may be used to adjust pH. Manufactured under license from Pharmacosmos A/S, Denmark Distributed by: Pharmacosmos Therapeutics Inc., Morristown, NJ 07960 For more information go to www.pharmacosmos.com or call 1-888-828-0655 .

Untitled section

Removed18 removed
Distributed by: Pharmacosmos Therapeutics Inc., Morristown, NJ 07960 Monoferric is manufactured under license from Pharmacosmos A/S, Denmark

Unchanged: Dosage forms and strengths, Nonclinical toxicology, PRINCIPAL DISPLAY PANEL - 100 mg/mL Vial Box, PRINCIPAL DISPLAY PANEL - 500 mg/5 mL Vial Box, PRINCIPAL DISPLAY PANEL - 1000 mg/10 mL Vial Box, PRINCIPAL DISPLAY PANEL- 10 mL Vial Single Dose.

Every version

10 versions of set 55859d2d-0456-4fa9-b41f-f535accc97db, newest first.
VersionPublished on DailyMedCompareSPL file
15Nov 4, 2026Shown belowDownload .zip
13Dec 10, 2025With version 12Download .zip
12Sep 20, 2024With version 11Download .zip
11Jan 17, 2024With version 10Download .zip
10Aug 22, 2022With version 9Download .zip
9Feb 8, 2022With version 8Download .zip
8Nov 17, 2021With version 7Download .zip
7Sep 16, 2020With version 6Download .zip
6Sep 11, 2020With version 1Download .zip
1May 22, 2020First versionDownload .zip

Read an SPL file

Open an SPL label file

Drop a Structured Product Labeling .xml file, or the .zip DailyMed downloads, to read it as a label. It is read in this browser tab and not uploaded.

Read in this browser tab; nothing is uploaded.

Versions and label text from DailyMed's SPL web services; a version's text is read from its SPL file, so it matches what DailyMed shows. Recent safety-related changes from FDA's Safety-related Labeling Changes database, which covers NDAs and CDER biologics, not generics. Lists refresh daily. DailyMed, National Library of Medicine

About label change history

How to read a comparison

Sections that changed come first, in the order a reviewer reads a label: boxed warning, recent major changes, indications, dosage, contraindications, warnings and precautions, adverse reactions, then the rest. Each shows the changed lines with one unchanged line either side; longer unchanged stretches are folded into a count. Table rows read left to right with cells separated by a bar.

The comparison covers the label text. Images, product data (NDC codes, ingredients, packaging) and formatting are not compared.

Which label is shown

A drug can have several labels: one per brand-name application (Ozempic, Wegovy and Rybelsus are three), and copies from repackagers. For each NDA or BLA the page takes the DailyMed set with the most versions, which is the application holder's. Generic labels are left out; they follow the brand's label.

Frequently asked questions

Where do the versions come from?
DailyMed, the National Library of Medicine's library of labels in Structured Product Labeling (SPL) format. Each time a company submits a revised label, DailyMed publishes it as a new version of the same set and keeps the old ones.
Is a new version a new FDA approval?
Not always. Companies also submit new versions for changes that need no FDA approval first, such as a new address, a new package size or a corrected typo. Safety changes FDA approved are listed in its Safety-related Labeling Changes database, linked below.
Why does the published date differ from the label's revised date?
The published date is when DailyMed posted the version. The label's own revised date, at the end of the highlights, is when the company revised the text, usually a few days to weeks earlier.
How is the comparison made?
Each section is matched by its standard LOINC code, then split into headings, paragraphs, list items and table rows. Lines are aligned with a longest-common-subsequence diff; a removed and an added line that share at least half their words are shown as one edited line with the changed words marked. Curly quotes, dash styles and spacing are ignored.
Is my SPL file uploaded?
No. A file you drop on this page is read in your browser tab and never sent to Arca.
Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.